Advertisement

Digitalis Glycosides

  • Ralph A. Kelly
  • Thomas W. Smith

Abstract

Cardiac glycosides have played a prominent role in the therapy of congestive heart failure since William Withering codified its use in his classic monograph on the efficacy of the leaves of the common foxglove plant (Digitalis purpurea) in 1785. However, a controversy has arisen in the past two decades about whether the risks of digitalis preparations outweigh their benefits, particularly in patients with heart failure in sinus rhythm.1 The standard for clinical use of the cardiac glycosides in modern medicine was reflected in a debate between two eminent clinicians, who were also the coeditors of the Oxford Medicine, Henry Christian and Sir James Mackenzie. Sir James Mackenzie advocated the use of digitalis preparations only in those patients with heart failure who also had atrial arrhythmias, prompting the following response from Christian: “My views evidently differ from those of my fellow editor of the Oxford Medicine.

Keywords

Cardiac Glycoside Positive Inotropic Effect Serum Digoxin Concentration Digoxin Toxicity Versus Block 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Withering W. An account of the foxglove and some of its medical uses, with practical remarks on dropsy, and other disease. In: Willius FA, Keys TE, eds. Classics of Cardiology. New York: Henry Schuman, Dover Publications; 1941;I:231–252.Google Scholar
  2. 2.
    Christian HA. Digitalis effects in chronic cardiac cases with regular rhythm in contrast to auricular fibrillation. Med Clin North Am. 1922;5:117–119.Google Scholar
  3. 3.
    Guntert TW, Linde HHA. Chemistry and structure-activity relationships of cardioactive steroids. In: Greeff K, ed. Handbook of Experimental Pharmacology, Vol. 56/I, Cardiac Glycosides. Berlin: Springer-Verlag; 1981: 13–24.Google Scholar
  4. 4.
    Marshall PG. Steroids: cardiotonic glycosides and aglycones; toad poisons. In: Coffy S, ed. Rodd’s Chemistry of Carbon Compounds, Vol. 2D, Steroids. Amsterdam: Elsevier; 1970.Google Scholar
  5. 5.
    Eisner DA, Smith TW. The Na-K pump and its effectors in cardiac muscle. In: Fozzard HA, Haber E, Katz AM, Morgan HE, eds. The Heart and Cardiovascular System. New York: Raven Press; 1992.Google Scholar
  6. 6.
    Thomas R, Gray P, Andrews J. Digitalis: its mode of action, receptor, and structure-activity relationships. In: Testa B, ed. Advances in Drug Research. New York: Academic Press; 1989:19.Google Scholar
  7. 7.
    Wiggers CJ, Stimson B. Studies on cardiodynamic action of drugs. III. The mechanism of cardiac stimulation by digitalis and g-strophanthin. J Pharmacol Exp Ther. 1927;30:251–269.Google Scholar
  8. 8.
    Sonnenblick EH, Williams JF Jr, Glick G, et al. Studies on digitalis. XV. Effects of cardiac glycosides on myocardial force-velocity relations in the nonfailing human heart. Circulation. 1966;34:532–539.PubMedGoogle Scholar
  9. 9.
    Arnold SB, Byrd RC, Meister W, et al. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med. 1980;303:1443–1448.PubMedGoogle Scholar
  10. 10.
    Lee DC-S, Johnson RA, Bingham JB, et al. Heart failure in outpatients. A randomized trial of digoxin versus placebo. N Engl J Med. 1982;306:699–705.PubMedGoogle Scholar
  11. 11.
    Reiter M. The positive inotropic action of cardiac glycosides on cardiac ventricular muscle. In: Greeff K, ed. Handbook of Experimental Pharmacology, Vol. 56/I, Cardiac Glycosides. Berlin: Springer-Verlag; 1981:187–210.Google Scholar
  12. 12.
    Koch-Weser J, Blinks JR. Analysis of the relation of the positive inotropic action of cardiac glycosides to the frequency of contraction of heart muscle. J Pharmacol Exp Ther. 1962;136:305–317.PubMedGoogle Scholar
  13. 13.
    Marban E, Tsien RW. Enhancement of cardiac calcium current during digitalis inotropy: positive feedback regulation by intracellular calcium? J Physiol (Lond). 1982;329:589–614.PubMedGoogle Scholar
  14. 14.
    Wier WG, Hess P. Excitation-contraction coupling in cardiac Purkinje fibers. Effects of cardiotonic steroids on the intracellular [Ca2+] transient, membrane potential, and contraction. J Gen Physiol. 1984;83:395–415.PubMedGoogle Scholar
  15. 15.
    Morgan JP, Blinks JR. Intracellular Ca2+ transients in the cat papillary muscle. Can J Physiol Pharmacol. 1982;60:524–528.PubMedGoogle Scholar
  16. 16.
    Kim D, Barry WH, Smith TW. Kinetics of ouabain binding and changes in cellular sodium content, 42K+ transport, and contractile state during ouabain exposure in cultured chick heart cells. J Pharmacol Exp Ther. 1984;231:326–333.PubMedGoogle Scholar
  17. 17.
    Biedert S, Barry WH, Smith TW. Inotropic effects and changes in sodium and calcium contents associated with inhibition of monovalent cation active transport by ouabain in cultured myocardial cells. J Gen Physiol. 1979;74:479–494.PubMedGoogle Scholar
  18. 18.
    Barry WH, Hasin Y, Smith TW. Sodium pump inhibition, enhanced Ca-influx via Na-Ca exchange, and positive inotropic response in cultured heart cells. Circ Res. 1985;56:231–241.PubMedGoogle Scholar
  19. 19.
    Eisner DA, Lederer WJ, Vaughan-Jones RD. The quantitative relationship between twitch tension and intracellular sodium activity in sheep cardiac Purkinje fibers. J Physiol. 1984;355:251–266.PubMedGoogle Scholar
  20. 20.
    Grupp I, Im WB, Lee CO, et al. Relation of sodium pump inhibition to positive inotropy at low concentrations of ouabain in rat heart muscle. J Physiol. 1985;360:149–160.PubMedGoogle Scholar
  21. 21.
    Skou JC. The Na,K-pump. In: Fleischer S, Fleischer B, eds. Methods in Enzymology. San Diego, CA: Academic Press; 1988;156:1–28.Google Scholar
  22. 22.
    Pedersen PL, Carafoli E. Ion motive ATPases. Trends Biol Sci. 1987;12:146–150, 186–189.Google Scholar
  23. 23.
    Shull GE, Lingrel JB. Molecular cloning of the rat stomach (H+-K+)-ATPase. J Biol Chem. 1986;261:16788–16791.PubMedGoogle Scholar
  24. 24.
    Shull GE, Young RM, Greeb G, et al. Amino acid sequences of the alpha and beta subunits of the Na,K-ATPase. In: Skou JC, Norby JG, Maunsbach AB, Esmann M, eds. The Na + , K + -Pump, Molecular Aspects. New York: Alan R Liss; 1988;l(Pt. A):3–18.Google Scholar
  25. 25.
    Gunteski-Hamblin AM, Greeb J, Shull GE. A novel Ca2+ pump expressed in brain, kidney and stomach is encoded by an alternative transcript of the slow-twitch muscle sarcoplasmic reticulum Ca-ATPase gene. J Biol Chem. 1988;263:15032–15040.PubMedGoogle Scholar
  26. 26.
    Jorgensen PL, Collins JH. Localization of tryptic and chymotryptic cleavage sites in alpha-subunit of Na,K-ATPase. In: Skou JC, Norby JG, Maunsbach AB, Esmann M, eds. The Na + ,K + -Pump, Molecular Aspects. New York: Alan R Liss; 1988; 1(Pt. A):85–92.Google Scholar
  27. 27.
    Lytton J, MacLennan DH. Molecular cloning of cDNAs from human kidney coding for two alternatively spliced products of the cardiac Ca2+-ATPase gene. J Biol Chem. 1988;263:15024–15031.PubMedGoogle Scholar
  28. 28.
    MacLennan DH, Brandi CJ, Korczak B, et al. Amino-acid sequence of a Ca2+ + Mg2+-dependent ATPase from rabbit muscle sarcoplasmic reticulum, deduced from its complementary DNA sequence. Nature. 1985; 316:696–700.PubMedGoogle Scholar
  29. 29.
    Shull GE, Schwartz A, Lingrel JB. Amino-acid sequence of the catalytic subunit of the (Na+ + K+)ATPase deduced from a complementary DNA. Nature. 1985; 316:691–695.PubMedGoogle Scholar
  30. 30.
    Shull GE, Lane LK, Lingrel JB. Amino-acid sequence of the beta-subunit of the (Na+ + K+)ATPase deduced from a cDNA. Nature. 1986;321:429–431.PubMedGoogle Scholar
  31. 31.
    Young RM, Shull GE, Lingrel JB. Multiple mRNAs from rat kidney and brain encode a single Na+,K+-ATPase beta subunit protein. J Biol Chem. 1987;262: 4905–4910.PubMedGoogle Scholar
  32. 32.
    Forbush B, Kaplan J, Hoffman JF. Characterization of a new photoaffinity derivative of ouabain labeling of the large polypeptides and of a proteolipid compound of the NaK-ATPase. Biochemistry. 1978;17:3667–3675.PubMedGoogle Scholar
  33. 33.
    Collins JH, Leszyk J. The “gamma subunit” of Na,K-ATPase: a small amphiphilic protein with a unique amino acid sequence. Biochemistry. 1987;26:8665–8668.PubMedGoogle Scholar
  34. 34.
    Forbush B. Cardiotonic steroid binding to NaK-ATPase. In: Hoffman JF, Forbush B, eds. Current Topics in Membrane Transport. New York: Academic Press; 1983:167–201.Google Scholar
  35. 35.
    Wallick ET, Schwartz A. Interaction of cardiac glycosides with Na+,K+-ATPase. In: Fleischer S, Fleischer B, eds. Methods in Enzymology. San Diego, CA: Academic Press; 1988;156:201–213.Google Scholar
  36. 36.
    Langer GA. Relationship between myocardial contractility and the effects of digitalis on ionic exchange. Fed Proc. 1977;36:2231–2234.PubMedGoogle Scholar
  37. 37.
    Eisner DA, Lederer WJ. The role of the sodium pump in the effects of potassium-depleted solutions on mammalian cardiac muscle. J Physiol. 1979;294:279–301.PubMedGoogle Scholar
  38. 38.
    Lederer WJ, Eisner DA. The effects of sodium pump activity on the slow inward current in sheep cardiac Purkinje fibers. Proc R Soc Lond. 1982;B214:249–262.Google Scholar
  39. 39.
    Lee KS, Marban E, Tsien RW. Inactivation of calcium channels in mammalian heart cells. Joint dependence on membrane potential and intracellular calcium. J Physiol. 1985;364:395–411.PubMedGoogle Scholar
  40. 40.
    Dagostino M, Lee CO. Neutral carrier Na+- and Ca2+-selective microelectrodes for intracellular application. Biophys J. 1982;40:199–207.PubMedGoogle Scholar
  41. 41.
    Smith TW, Braunwald E, Kelly RA. Management of congestive heart failure. In: Braunwald E, ed. Heart Disease. 4th ed. Philadelphia: Saunders; 1992.Google Scholar
  42. 42.
    Smith TW, ed. Digitalis Glycosides. Orlando: Grune & Stratton; 1986.Google Scholar
  43. 43.
    Watanabe AM. Digitalis and the autonomic nervous system. J Am Coll Cardiol. 1985;5(Suppl A):35A–42A.PubMedGoogle Scholar
  44. 44.
    Rosen MR. Cellular electrophysiology of digitalis toxicity. J Am Coll Cardiol. 1985;5(Suppl A):22A–34A.PubMedGoogle Scholar
  45. 45.
    Dhingra RC, Amat-Y-Leon F, Wyndham C, et al. The electrophysiological effects of ouabain on sinus node and atrium in man. J Clin Invest. 1975;56:555–562.PubMedGoogle Scholar
  46. 46.
    Goodman DJ, Rossen RM, Ingham R, et al. Sinus node function in the denervated human heart: effects of digitalis. Br Heart J. 1975;37:612–618.PubMedGoogle Scholar
  47. 47.
    Somberg JC, Smith TW. Localization of the neurally-mediated arrhythmogenic properties of digitalis. Science. 1979;204:321–323.PubMedGoogle Scholar
  48. 48.
    Somberg JC, Risler TG, Smith TW. Neural factors in digitalis toxicity: protective effect of C-1 spinal cord transection. Am J Physiol. 1978;235:H531–H536.PubMedGoogle Scholar
  49. 49.
    Rosen MR. Interactions of digitalis with the autonomic nervous system and their relationship to cardiac arrhythmias. In: Disturbances in Neurogenic Control of the Circulation. Bethesda, MD: American Physiological Society; 1981:251–263.Google Scholar
  50. 50.
    Packer M, ed. Role of the sympathetic nervous system in heart failure: basic mechanisms and clinical directions. Circulation.1990;82(Suppl I):I-1–I-13.Google Scholar
  51. 51.
    Ferguson DW, Berg WJ, Sanders JS, et al. Sympa-thoinhibitory responses to digitalis glycosides in heart failure patients: direct evidence from sympathetic neural recordings. Circulation. 1989;80:65–77.PubMedGoogle Scholar
  52. 52.
    Lindenbaum J, Rund DG, Butler VP Jr. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med. 1981;305:789–794.PubMedGoogle Scholar
  53. 53.
    Halkin H, Sheiner LB, Peck CC, et al. Determinants of the renal clearance of digoxin. Clin Pharmacol Ther. 1975;17:385–394.PubMedGoogle Scholar
  54. 54.
    Cogan JJ, Humphreys MH, Carlson CJ, et al. Acute vasodilator therapy increases renal clearance of digoxin in pateints with congestive heart failure. Circulation. 1981;64:973–976.PubMedGoogle Scholar
  55. 55.
    Linday LA, Drayer DE, Khan MAA, et al. Pubertal changes in net renal tubular secretion of digoxin. Clin Pharmacol Ther. 1984;35:438–446.PubMedGoogle Scholar
  56. 56.
    Lindenbaum J, Mellow MH, Blackstone MO, et al. Variation in biologic availability of digoxin from four preparations. N Engl J Med. 1971;285:1344–1347.PubMedGoogle Scholar
  57. 57.
    Johnson BF, Lindenbaum J, Budnitz E, et al. Variability of steady-state digoxin kinetics during administration of tablets or capsules. Clin Pharmacol Ther. 1986;39:306–312.PubMedGoogle Scholar
  58. 58.
    Leahey EB Jr, Reiffei JA, Drusin RE, et al. Interaction between quinidine and digoxin. JAMA. 1978;240:533–534.PubMedGoogle Scholar
  59. 59.
    Seiden R, Margolies MN, Smith TW. Renal and gastrointestinal excretion of ouabain in dog and man. J Pharmacol Exp Ther. 1974;188:615–623.Google Scholar
  60. 60.
    Cardiac Glycosides. Part II: pharmacokinetics and clinical pharmacology. In: Greeff K, ed. Handbook of Experimental Pharmacology. Berlin: Springer-Verlag; 1981; 56.Google Scholar
  61. 61.
    Blatt CM, Marsh JD, Smith TW. Extracardiac effects of digitalis. In: Smith TW, ed. Digitalis Glycosides. Orlando: Grune & Stratton; 1985:209–215.Google Scholar
  62. 62.
    Sagar KB, Hanson EC, Powell WJ. Neurogenic coronary vasoconstrictor effects of digitalis during acute global ischemia in dogs. J Clin Invest. 1977;60:1248–1257.PubMedGoogle Scholar
  63. 63.
    Jelliffe RW, Brooker G. A nomogram for digoxin therapy. Am J Med. 1974;57:63–68.PubMedGoogle Scholar
  64. 64.
    Hougen TJ. Use of digoxin in the young. In: Smith TW, ed. Digitalis Glycosides. Orlando: Grune & Stratton; 1985:169–208.Google Scholar
  65. 65.
    Antman EM, Smith TW. Drug interactions with digitalis glycosides. In: Smith TW, ed. Digitalis Glycosides. Orlando: Grune & Stratton; 1985:65–82.Google Scholar
  66. 66.
    Marcus FI. Pharmacokinetic interactions between digoxin and other drugs. J Am Coll Cardiol. 1985;5:82A–90A.PubMedGoogle Scholar
  67. 67.
    Kuhlmann J, Marcin S. Effects of verapamil on pharmacokinetics and pharmacodynamics of digitoxin in patients. Am Heart J. 1985;110:1245–1250.PubMedGoogle Scholar
  68. 68.
    Elkayam U, Parikh K, Torkan B, et al. Effect of dil-tiazem on renal clearance and serum concentration of digoxin in patients with cardiac disease. Am J Cardiol. 1985;55:1393–1395.PubMedGoogle Scholar
  69. 69.
    Lessem J, Bellinetto A. Interaction between digoxin and calcium antagonists. Am J Cardiol. 1982;49:1025.Google Scholar
  70. 70.
    Moysey JO, Jaggarao NSV, Grundy EN, et al. Amio-darone increases plasma digoxin concentrations. Br Med J. 1981;282:272.Google Scholar
  71. 71.
    Nademanee K, Kannan R, Hendrickson J, et al. Amiodarone-digoxin interaction during treatment of resistant cardiac arrhythmias. Am J Cardiol. 1982;49:1026.Google Scholar
  72. 72a.
    Braunwald E. Effects of digitalis on the normal and the failing heart. J Am Coll Cardiol. 1985;5:51A–59A.PubMedGoogle Scholar
  73. 72b.
    Gheorghiade M, Ferguson D. Digoxin. A neurohormonal modulation in heart failure. Circulation. 1991; 84:2181–2186.PubMedGoogle Scholar
  74. 73.
    Cantelli I, Vitolo A, Lombardi G, et al. Combined hemodynamic effects of digoxin and Captopril in patients with congestive heart failure. Curr Ther Res. 1984;36: 323–331.Google Scholar
  75. 74.
    Bostrom PA, Andersson J, Johansson BW, et al. Hemodynamic effects of prenalterol and cardiac glycosides in patients with recent myocardial infarction. Eur J Clin Invest. 1984;14:175–180.PubMedGoogle Scholar
  76. 75.
    Starr I, Luchi RJ. Blind study on the action of digitoxin on elderly women. Am Heart J. 1969;78:740–751.PubMedGoogle Scholar
  77. 76.
    Dobbs SN, Kenyon WI, Dobbs RJ. Maintenance digoxin after an episode of heart failure. Placebo controlled trial in outpatients. Br Med J. 1977;1:749–752.PubMedGoogle Scholar
  78. 77.
    Fleg L, Gottlieb SH, Lakatta EG. Is digoxin really important in compensated heart failure? Am J Med. 1982;73:244–250.PubMedGoogle Scholar
  79. 78.
    Taggart AJ, Johnston GD, McDevitt DG. Digoxin withdrawal after cardiac failure in patients with sinus rhythm. J Cardiovasc Pharmacol. 1983;5:229–234.PubMedGoogle Scholar
  80. 79.
    Guyatt GH. The treatment of heart failure. A methodological review of the literature. Drugs. 1986;32:538–568.PubMedGoogle Scholar
  81. 80.
    Gheorghiade M, St. Clair J, St. Clair C, et al. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J Am Coll Cardiol. 1987;9:849–857.PubMedGoogle Scholar
  82. 81.
    Alicandri C, Fariello R, Boni E, et al. Captopril versus digoxin in mild-moderate chronic heart failure: a crossover study. J Cardiovasc Pharmacol. 1987;9:S61–S67.PubMedGoogle Scholar
  83. 82.
    Guyatt GH, Sullivan MJJ, Fallen EL, et al. A controlled trial of digoxin in congestive heart failure. Am J Cardiol. 1988;61:371–375.PubMedGoogle Scholar
  84. 83.
    German and Austrian Xamoterol Study Group. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet. 1988;1:489–493.Google Scholar
  85. 84.
    Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet. 1990;336:1–6.Google Scholar
  86. 85.
    Anon. Editorial. New evidence on xamoterol. Lancet. 1990;336:24.Google Scholar
  87. 86.
    Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with Captopril and digoxin in patients with mild to moderate heart failure. JAMA. 1988;259:539–544.Google Scholar
  88. 87.
    DiBianco R, Shabetai R, Kostuk W, et al. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 1989;320:677–683.PubMedGoogle Scholar
  89. 88.
    Gheorghiade M, Hall V, Lakier JB, et al. Comparative hemodynamic and neurohormonal effects of intravenous Captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol. 1989; 13:134–142.PubMedGoogle Scholar
  90. 89.
    Ribner HS, Zucker MJ, Stasior C, et al. Vasodilators as first-line therapy for congestive heart failure: a comparative hemodynamic study of hydralazine, digoxin and their combination. Am Heart J. 1987;114:91–96.PubMedGoogle Scholar
  91. 90.
    Cantelli I, Vitolo A, Lombardi G, et al. Combined hemodynamic effects of digoxin and Captopril in patients with congestive heart failure. Curr Ther Res. 1984; 36:323–331.Google Scholar
  92. 91.
    Sullivan M, Atwood JE, Myers J, et al. Increased exercise capacity after digoxin administration in patients with heart failure. J Am Coll Cardiol. 1989;13:1138–1142.PubMedGoogle Scholar
  93. 92.
    Pugh SE, White NJ, Aronson JK, et al. Clinical, hemodynamic, and pharmacological effects of withdrawal and reintroduction of digoxin in patients with heart failure in sinus rhythm after long-term treatment. Br Heart J. 1989;61:529–539.PubMedGoogle Scholar
  94. 93.
    Fleg JL, Rothfeld B, Gottlieb SH. Effect of maintenance digoxin Therapy on aerobic performance and exercise left ventricular function in mild to moderate heart failure due to coronary artery disease: a randomized, placebo-controlled crossover trial. J Am Coll Cardiol. 1991;17: 743–751.PubMedGoogle Scholar
  95. 94.
    Mohan P, Hii JTY, Wuttke RD, et al. Acute heart failure: determinants of outcome. Int J Cardiol. 1991; 32:365–376.PubMedGoogle Scholar
  96. 95.
    Young JB, Uretsky BF, Shahidi E, et al. Multicenter, double-blind, placebo-controlled randomized withdrawal trial of the efficacy and safety of digoxin in patients with mild to moderate chronic heart failure not treated with converting enzyme inhibitors. J Am Coll Cardiol. 1992; 19:259A.Google Scholar
  97. 96.
    Packer M, Gheorghiade M, Young JB, et al. Randomized, double-blind, placebo-controlled, withdrawal study of digoxin in patients with chronic heart failure treated with converting-enzyme inhibitors. J Am Coll Cardiol. 1992;19:260A.Google Scholar
  98. 97.
    Kelly RA, Smith TW. Digoxin in heart failure: Implications of recent trials. J Am Coll Cardiol. 1993; (in Press).Google Scholar
  99. 98.
    Beiser GD, Epstein SE, Stampfer M, et al. Studies on digitalis. XVII. Effects of ouabain on the hemodynamic response to exercise in patients with mitral stenosis in normal sinus rhythm. N Engl J Med. 1968;278:131–137.PubMedGoogle Scholar
  100. 99.
    Antman E. Medical management of the patient undergoing cardiac surgery. In: Braunwald E, ed. Heart Disease. 4th ed. Philadelphia: Saunders; 1992.Google Scholar
  101. 100.
    Johnson LW, Dickstein RA, Freuhan CT, et al. Prophylactic digitalization for coronary artery bypass surgery. Circulation. 1976;53:819–822.PubMedGoogle Scholar
  102. 101.
    Tyras DH, Stothert JC Jr, Kaiser GC, et al. Supraventricular tachyarrhythmias after myocardial revascularization: a randomized trial of prophylactic digitalization. J Thorac Cardiovasc Surg. 1979;77:310–314.PubMedGoogle Scholar
  103. 102.
    Antman EM, Friedman PL. Use of digitalis glycosides in the management of cardiac arrhythmias. In: Smith TW, ed. Digitalis Glycosides. Orlando: Grune & Stratton; 1985:127–151.Google Scholar
  104. 103.
    Surawicz B. Supraventricular arrhythmias. In: Messerli FH, ed. Cardiovascular Drug Therapy. Philadelphia: Saunders; 1990:1150–1166.Google Scholar
  105. 104.
    Bigger JT Jr, Hoffman BF. Antiarrhythmic drugs. In: Gilman AG, Rail TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon Press; 1990:840–873.Google Scholar
  106. 105.
    Falk RH, Knowlton AA, Bernard SA, et al. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: a randomized, double-blinded trial. Ann Intern Med. 1987;106:503–506.PubMedGoogle Scholar
  107. 106.
    Simpson RJ, Foster JR, Woelfel AK, et al. Management of atrial fibrillation and flutter—a reappraisal of digitalis therapy. Postgrad Med. 1986;79:241–253.PubMedGoogle Scholar
  108. 107.
    Beasley R, Smith DA, McHaffie DJ. Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation. Br Med J. 1985;290:9–11.Google Scholar
  109. 108.
    Zoble RG, Brewington J, Olukotun AY, et al. Use of beta-blockers as antiarrhythmic agents. Comparative effects of nadolol-digoxin combination therapy and digoxin monotherapy for chronic atrial fibrillation. Am J Cardiol. 1987;60:39D–45D.PubMedGoogle Scholar
  110. 109.
    Ahuja RC, Sinha N, Saran RK, et al. Digoxin or verapamil or metoprolol for heart rate control in patients with mitral stenosis—a randomized crossover study. Int J Cardiol. 1989;25:325–331.PubMedGoogle Scholar
  111. 110.
    Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J. 1990;63:225–227.PubMedGoogle Scholar
  112. 111.
    Sellers TD, Bashore TM, Gallagher JJ. Digitalis in preexcitation syndrome—analysis during atrial fibrillation. Circulation. 1977;56:260–267.PubMedGoogle Scholar
  113. 112.
    Kelly RA. Cardiac glycosides and congestive heart failure. Am J Cardiol. 1990;65:10E–16E.Google Scholar
  114. 113.
    Smith TW, Antman EM, Friedman PL, et al. Digitalis glycosides: mechanisms and manifestations of toxicity. Part I. Prog Cardiovasc Dis. 1984;26:414–458.Google Scholar
  115. 114.
    Hoffman BF, Bigger JT Jr. Digitalis and allied cardiac glycosides. In: Gilman AG, Rail TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon Press; 1990:814–839.Google Scholar
  116. 115.
    Lown B, Wyatt NF, Levine HD. Paroxysmal atrial tachycardia with block. Circulation. 1960;21:129–143.PubMedGoogle Scholar
  117. 116.
    Fisch C, Knoebel SB. Accelerated junctional escape: a clinical manifestation of “triggered” automaticity. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology and Arrhythmias. New York: Grune & Stratton; 1985:467.Google Scholar
  118. 117.
    Eisendrath SJ, Sweeney MA. Toxic neuropsychiatrie effects of digoxin at therapeutic serum concentrations. Am J Psychiatry. 1987;144:506–507.PubMedGoogle Scholar
  119. 118.
    Blatt CM, Marsh JD, Smith TW. The role of neural factors in digitalis intoxication. In: Smith TW, ed. Digitalis Glycosides. Orlando: Grune & Stratton; 1985:277–294.Google Scholar
  120. 119.
    Klausen T, Kjeldsen K, Norgaard A. Effects of denervation on sodium, potassium and [H3]ouabain binding in muscles of normal and potassium depleted rats. J Physiol. 1983;345:123–134.Google Scholar
  121. 120.
    Ferrier GR, Saunders JH, Méndez C. A cellular mechanism for the generation of ventricular arrhythmias by acetylstrophanthidin. Circ Res. 1973;32:600–609.PubMedGoogle Scholar
  122. 121.
    Whang R, Qei TO, Watanabe A. Frequency of hypo-magnesemia in hospitalized patients receiving digitalis. Arch Intern Med. 1985;145:655–656.PubMedGoogle Scholar
  123. 122.
    Smith TW, Butler VP Jr, Haber E, et al. Treatment of life-threatening digitalis intoxication with digoxin-specific Fab fragments: experience in 26 cases. N Engl J Med. 1982;307:1357–1362.PubMedGoogle Scholar
  124. 123.
    Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981;63:1285–1288.PubMedGoogle Scholar
  125. 124.
    Vogel R, Kirch D, LeFree M, et al. Effects of digitalis on resting and isometric exercise myocardial perfusion in patients with coronary artery disease and left ventricular dysfunction. Circulation. 1977;56:355–359.PubMedGoogle Scholar
  126. 125.
    Crawford MH, LeWinter MM, O’Rourke RA, et al. Combined propranolol and digoxin therapy in angina pectoris. Ann Intern Med. 1975;83:449–455.PubMedGoogle Scholar
  127. 126.
    Lown B, Klein MD, Barr I, et al. Sensitivity to digitalis drugs in acute myocardial infarction. Am J Cardiol. 1972;30:388–395.PubMedGoogle Scholar
  128. 127.
    Reicansky I, Conradson TB, Holmberg S, et al. The effect of intravenous digoxin on the occurrence of ventricular tachyarrhythmias in acute myocardial infarction in man. Am Heart J. 1976;91:705–711.PubMedGoogle Scholar
  129. 128.
    Moss AJ, Davis HT, Conard DL, et al. Digitalis-associated cardiac mortality after myocardial infarction. Circulation. 1981;64:1150–1156.PubMedGoogle Scholar
  130. 129.
    Bigger JT, Fleiss JL, Rolnitzky LM, et al. Effect of digitalis treatment on survival after acute myocardial infarction. Am J Cardiol. 1985;55:623–630.PubMedGoogle Scholar
  131. 130.
    Ryan TJ, Bailey KR, McCabe CH, et al. The effects of digitalis on survival in high-risk patients with coronary artery disease. Circulation. 1983;67:735–742.PubMedGoogle Scholar
  132. 131.
    Madsen EB, Gilpin E, Henning H, et al. Prognostic importance of digitalis after acute myocardial infarction. J Am Coll Cardiol. 1984;3:681–689.PubMedGoogle Scholar
  133. 132.
    Byington R, Goldstein S, and the BHAT Research Group. Association of digitalis therapy with mortality in survivors of acute myocardial infarction: observations in the beta-blocker heart attack trial. J Am Coll Cardiol. 1985;6:976–982.PubMedGoogle Scholar
  134. 133.
    Muller JE, Turi ZG, Stone PH, et al. Digoxin therapy and mortality after myocardial infarction: experience in the MILIS study. N Engl J Med. 1986;314:265–271.PubMedGoogle Scholar
  135. 134.
    Szefler SJ, Jusko WJ. Decreased volume of distribution of digoxin in a patient with renal failure. Res Commun Chem Pathol Pharmacol. 1973;6:1095–1098.PubMedGoogle Scholar
  136. 135.
    Friedman PL, Antman EM, Smith TW. Clinical management of digitalis toxicity. In: Smith TW, ed. Digitalis Glycosides. Orlando: Grune & Stratton; 1985:295–309.Google Scholar
  137. 136.
    Ditchey RV, Karliner JS. Safety of electrical cardioversion in patients without digitalis toxicity. Ann Intern Med. 1981;95:676–679.PubMedGoogle Scholar
  138. 137.
    Antman EM, Wenger TL, Butler VP Jr, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: final report of a multicenter study. Circulation. 1990;81:1744–1752.PubMedGoogle Scholar
  139. 138.
    Hickey AR, Wenger TL, Carpenter VP, et al. Digoxin immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol. 1991;17:590–598.PubMedGoogle Scholar
  140. 139.
    Woolf AD, Wenger T, Smith TW, Lovejoy FH. The use of digoxin-specific Fab fragments for severe digitalis intoxication in children. N Engl J Med. 1992;326:1739–1744.PubMedGoogle Scholar
  141. 140.
    Mahdyoon H, Battilana G, Rosman H, et al. The evolving pattern of digoxin intoxication: observations at a large urban hospital from 1980 to 1988. Am Heart J. 1990;120:1189–1194.PubMedGoogle Scholar
  142. 141.
    Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol. 1992;69:1086–1196.Google Scholar
  143. 142.
    Smith TW. Serum and plasma cardiac glycoside concentrations: clinical use and misuse. In: Smith TW, ed. Digitalis Glycosides. Orlando: Grune & Stratton; 1985:153–167.Google Scholar
  144. 143.
    Doering W, Konig E, Sturm W. Digitalis intoxication: specificity and significance of cardiac and extracardiac symptoms. I. Patients with digitalis-induced arrhythmias. Z Kardiol. 1977;66:121–128.PubMedGoogle Scholar
  145. 144.
    Eraker SA, Sasse L. The serum digoxin test and digoxin toxicity: a Bayesian approach to decision making. Circulation. 1981;64:409–420.PubMedGoogle Scholar
  146. 145.
    Kelly RA, Smith TW. The search for the endogenous digitalis: an alternative hypothesis. Am J Physiol. 1989; 25:C737–C950.Google Scholar
  147. 146.
    Goto A, Yamada K, Yagi N, et al. Physiology and pharmacology of endogenous digitalis-like factors. Pharmacol Rev. 1992;44:377–399.PubMedGoogle Scholar
  148. 147.
    Hamlyn JM, Blaustein MP, Bova S, et al. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci USA. 1991;88:6259–6263.PubMedGoogle Scholar
  149. 148.
    Gottlieb SS, Rogowski AC, Weinberg M, et al. Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation. 1992;86:420–425.PubMedGoogle Scholar
  150. 149.
    Kelly RA, Smith TW. Is ouabain the endogenous digitalis? Circulation. 1992;86:694–697.PubMedGoogle Scholar
  151. 150.
    Graves SW, Brown B, Valdes R. An endogenous digoxin-like substance in patients with renal impairment. Ann Intern Med. 1983;99:604–608.PubMedGoogle Scholar
  152. 151.
    Kramer HJ, Heppe M, Weiler E, et al. Further characterization of the endogenous natriuretic and digoxin-like immunoreacting activities in human urine: effects of changes in sodium intake. Renal Physiol. 1985;8:80–89.PubMedGoogle Scholar
  153. 152.
    Graves SW, Williams GH. An endogenous ouabain-like factor associated with hypertensive pregnant women. J Clin Endocrinol Metab. 1984;59:1070–1074.PubMedGoogle Scholar
  154. 153.
    Seccombe DW, Pudek MR, Whitfield et al. Perinatal changes in a digoxin-like immunoreactive substance. Pediatr Res. 1984;18:1097–1099.PubMedGoogle Scholar
  155. 154.
    Graves SW, Valdes R, Brown BA, et al. Endogenous digoxin-immunoreactive substance in human pregnancies. J Clin Endocrinol Metab. 1984;58:748–751.PubMedGoogle Scholar
  156. 155.
    Vinge E, Helgessen-Rosendal S, Backstrom T. Progesterone, some progesterone derivatives and urinary digoxin-like substances from pregnant women in radio-immuno- and 85Rb uptake assays of digoxin. Pharmacol Toxicol. 1988;63:277–280.PubMedGoogle Scholar
  157. 156.
    Koren G, Farine D, Grundmann H, et al. Endogenous digoxin-like substance (s) associated with uneventful and high-risk pregnancies. Dev Pharmacol Ther. 1988;11:82–87.PubMedGoogle Scholar
  158. 157.
    Shrivastav P, Gill DS, D’Souza V, et al. Secretion of atrial natriuretic peptide and digoxin-like immunoreactive substance during pregnancy. Clin Chem. 1988;34: 977–980.PubMedGoogle Scholar
  159. 158.
    Longerich L, Brent DA, Johnson RL, et al. Identification of progesterone and Cortisol as immunoreactive plasma digitalis-like factors in pregnancy. Res Commun Chem Pathol Pharmacol. 1988;59:383–393.PubMedGoogle Scholar
  160. 159.
    Goodlin RC. Fetal endoxin and pregnancy complication. Am J Obstet Gynecol. 1988;158(Pt 1):529–530.PubMedGoogle Scholar
  161. 160.
    Phelps SJ, Cochran EB, Gonzalez-Ruiz A, et al. The influence of gestational age and preeclampsia on the presence and magnitude of serum endogenous digoxin-like immunoreactive substance(s). Am J Obstet Gynecol. 1988;158:34–39.PubMedGoogle Scholar
  162. 161.
    Weiner CP, Robillard JE. Atrial natriuretic factor, digoxin-like immunoreactive substance, norepinephrine, epinephrine, and plasma renin activity in human fetuses and their alteration by fetal disease. Am J Obstet Gynecol. 1988;159:1353–1360.PubMedGoogle Scholar
  163. 162.
    Gonzalez AR, Phelps SJ, Cochran EB, et al. Digoxin-like immunoreactive substance in pregnancy. Am J Obstet Gynecol. 1987;157:660–664.PubMedGoogle Scholar
  164. 163.
    Rauch AL, Buckalew VM Jr. Characterization of a competitive and reversible ligand to E2 conformation of Na,K-ATPase molecule. Biochem Biophys Res Commun. 1988;150:648–654.PubMedGoogle Scholar
  165. 164.
    Kelly RA. Excretion of artifactual endogenous digitalislike factors. Am J Physiol. 1986;251:H205–H209.PubMedGoogle Scholar
  166. 165.
    Diamandis EP, Papanastasiou-Diamandis A, Soldin SJ. Digoxin immunoreactivity in cord and maternal serum and placental extracts: partial characterization of immunoreactive substances by high-performance liquid chromatography and inhibition of Na+,K+-ATPase. Clin Biochem. 1985;18:48–55.PubMedGoogle Scholar
  167. 166.
    Soldin SJ. Digoxin—issues and controversies. Clin Chem. 1986;32:5–12.PubMedGoogle Scholar
  168. 167.
    Stone JA, Soldin SJ. Improved liquid chromatographic/immunoassay of digoxin in serum. Clin Chem. 1988; 34:2547–2551.PubMedGoogle Scholar
  169. 168.
    Longerich L, Vasdev S, Johnson E, et al. Disposable-column radioimmunoassay for serum digoxin with less interference from metabolites and endogenous digitalislike factors. Clin Chem. 1988;34:2211–2216.PubMedGoogle Scholar
  170. 169.
    Vinge E, Ekman R. Evaluation of crossreactivity of urinary digoxin-like substance in different radioimmunoassay. Ther Drug Monit. 1988;10:316–320.PubMedGoogle Scholar
  171. 170.
    Lau BW, Valdes R Jr. Criteria for identifying endogenous compounds as digoxin-like immunoreactive factors in humans. Clin Chim Acta. 1988;175:67–77.PubMedGoogle Scholar
  172. 171.
    Dasgupta A, Malik S, Ahmad S, et al. Mass spectrometry studies of a novel digoxin-like substance (DLIS-2) isolated from human plasma ultrafiltrate. Biochem Biophys Res Commun. 1988;152:1435–1440.PubMedGoogle Scholar
  173. 172.
    Yannakou L, Diamandis EP, Souvatzoglou A. Effect of incubation time and temperature on the interference of digoxin-like immunoreactive substances in digoxin immunoassays. Ther Drug Monit. 1987;9:461–463.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1994

Authors and Affiliations

  • Ralph A. Kelly
  • Thomas W. Smith

There are no affiliations available

Personalised recommendations